Revolution Medicines (FRA:42Z) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


FRA:42Z Revolution Medicines Inc FRA:42Z
30 GF Score
Price €157.20
GF Value €0.39
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Revolution Medicines Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Revolution Medicines's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:42Z vs ONC, ALNY, RPRX: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Revolution Medicines's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revolution Medicines Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revolution Medicines's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Revolution Medicines's Margin of Safety % (DCF Earnings Based) falls into.


FRA:42Z
30GF Score
Revolution Medicines Inc FRA:42Z
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Revolution Medicines (FRA:42Z) Overvalued in 2026?

Based on GuruFocus' analysis, Revolution Medicines stock appears to be overvalued. The current stock price of €157.20 is trading 40207.7% above its estimated GF Value™ of €0.39. GuruFocus considers Revolution Medicines to be Significantly Overvalued.

Key valuation signals for FRA:42Z:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €0.39 vs. price of €157.20 (40207.7% above fair value)
  • GF Score™: 30/100 with 4 warning signs

No single metric tells the full story. See the FRA:42Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Revolution Medicines Business Description

Address 700 Saginaw Drive, Redwood City, CA, USA, 94063
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
30GF Score

Get the complete analysis for FRA:42Z

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€157.20
Price
€0.39
GF Value